🇺🇸 FDA
Patent

US 12018045

17-beta-hydroxywithanolides and use thereof in treating cancer

granted A61KA61K31/404A61K31/58

Quick answer

US patent 12018045 (17-beta-hydroxywithanolides and use thereof in treating cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/404, A61K31/58, A61K31/635, A61K45/06